Arbutus Biopharma Corp: directors' dealings · United States · SEC (Form 4)

About Arbutus Biopharma Corp

Arbutus Biopharma Corp. (ticker: ABUS) is a U.S.-listed clinical-stage biopharmaceutical company traded on the Nasdaq market in the United States. For investors, it represents a focused biotech story rather than a diversified pharmaceutical platform: the company is centered on virology, with chronic hepatitis B (HBV) as its core therapeutic priority. Arbutus is headquartered in Warminster, Pennsylvania, and has built its identity around antiviral drug development and delivery technologies, especially lipid nanoparticle (LNP) science, which has become an increasingly strategic asset for the company. ([arbutusbio.com](https://www.arbutusbio.com/)) The company’s history dates back to Tekmira Pharmaceuticals, which adopted the Arbutus Biopharma name in 2015 as it sharpened its focus on finding solutions for chronic hepatitis B. That transition was more than cosmetic: it reflected a strategic narrowing toward HBV and toward combination regimens designed to attack the virus through multiple mechanisms. Arbutus now frames its development strategy through a “Suppress, Reduce, Boost” approach, aiming to block viral replication, reduce viral antigens, and stimulate the host immune response in a coordinated way. ([arbutusbio.gcs-web.com](https://arbutusbio.gcs-web.com/news-releases/news-release-details/tekmira-announces-launch-arbutus-biopharma-hepatitis-b-solutions?utm_source=openai)) The company’s lead clinical asset is imdusiran, an RNAi therapeutic designed for chronic HBV. Arbutus is also advancing AB-101, an oral PD-L1 inhibitor, in early-stage clinical testing. In recent company updates, management highlighted encouraging functional-cure signals in phase 2a studies of imdusiran, as well as favorable early safety and receptor-occupancy data for AB-101. This gives ABUS a classic clinical-biotech profile: high upside if data continue to improve, but meaningful execution and development risk if clinical responses plateau or safety/tolerability becomes an issue. ([arbutusbio.gcs-web.com](https://arbutusbio.gcs-web.com/news-releases/news-release-details/arbutus-reports-first-quarter-2025-financial-results-and)) A second major pillar of the investment case is intellectual property. Arbutus owns valuable LNP-related patents and technology, and those assets have been central to its litigation and licensing economics. In 2026, the company announced a global settlement with Moderna over alleged patent infringement tied to LNP delivery technology, with a large upfront payment expected later in the year. That settlement materially improved Arbutus’ financial profile and may support capital-return discussions, while the company also continues to support related legal efforts involving Pfizer/BioNTech through Genevant. ([investor.arbutusbio.com](https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-fourth-quarter-and-year-end-2025-financial)) Geographically, Arbutus’ operational footprint is U.S.-based, with its headquarters in Pennsylvania, but its commercial relevance is global because chronic hepatitis B is a worldwide disease area and because its technology and patent disputes have implications across the broader nucleic-acid delivery ecosystem. In short, ABUS is a specialized infectious-disease biotech on Nasdaq in the United States, with a pipeline-led story supplemented by monetizable IP and major legal catalysts. ([arbutusbio.com](https://www.arbutusbio.com/))